Don't Jump to DOACs First-Line for Cancer-Related VTE

We're getting questions about whether to use a direct oral anticoagulant (DOAC) in patients with cancer-associated thromboembolism.

The role of DOACs (apixaban, rivaroxaban, etc) is expanding. Chest guidelines now favor these meds for most patients with venous thromboembolism (VTE)...deep vein thrombosis or pulmonary embolism.

But don't jump to a DOAC first-line to treat or prevent recurrent VTE in cancer patients...due to limited efficacy and safety data.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals